CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+9.06%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$14.6B
AUM Growth
+$2.59B
(+22%)
Cap. Flow
+$828M
Cap. Flow
% of AUM
5.67%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
968
New
130
Increased
364
Reduced
334
Closed
74
Top Buys
| 1 |
Microsoft
MSFT
|
$144M |
| 2 |
Royal Bank of Canada
RY
|
$123M |
| 3 |
Agilent Technologies
A
|
$78.5M |
| 4 |
UnitedHealth
UNH
|
$71.8M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$70.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$92.6M |
| 2 |
Amgen
AMGN
|
$87.9M |
| 3 |
Allstate
ALL
|
$52.7M |
| 4 |
PayPal
PYPL
|
$47.9M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$47.4M |
Sector Composition
| 1 | Healthcare | 33.43% |
| 2 | Technology | 23.21% |
| 3 | Consumer Discretionary | 9.15% |
| 4 | Financials | 8.64% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Cigna
CI
$81.5B
| $8.96M | 0.06% |
37,794
-57,279
| -60% | -$13.6M |
|
302
IDEX
IEX
$12.4B
| $8.83M | 0.06% |
40,134
+31,397
| +359% | +$6.91M |
|
303
Charter Communications
CHTR
$35.7B
| $8.74M | 0.06% |
12,108
-9,953
| -45% | -$7.18M |
|
304
American Express
AXP
$227B
| $8.71M | 0.06% |
52,729
-37,433
| -42% | -$6.18M |
|
305
Waters Corp
WAT
$18.2B
| $8.68M | 0.06% |
25,112
+18,988
| +310% | +$6.56M |
|
306
ESSA Pharma
EPIX
$11M
| $8.59M | 0.06% |
300,525
+300,508
| +1,767,694% | +$8.59M |
|
307
NeoGenomics
NEO
$1.03B
| $8.46M | 0.06% |
187,332
-109,187
| -37% | -$4.93M |
|
308
Okta
OKTA
$16.1B
| $8.26M | 0.06% |
33,765
+11,789
| +54% | +$2.88M |
|
309
CSX Corp
CSX
$60.6B
| $8.26M | 0.06% |
257,349
+83,310
| +48% | +$2.67M |
|
|
VRAY
310
DELISTED
ViewRay, Inc.
VRAY
| $8.18M | 0.06% |
1,239,892
+378,930
| +44% | +$2.5M |
|
311
MetLife
MET
$52.9B
| $8.18M | 0.06% |
136,688
-174,441
| -56% | -$10.4M |
|
312
Marriott International Class A Common Stock
MAR
$71.9B
| $8.15M | 0.06% |
59,667
+38,838
| +186% | +$5.3M |
|
313
Personalis
PSNL
$465M
| $8.14M | 0.06% |
321,867
+110,551
| +52% | +$2.8M |
|
314
Hasbro
HAS
$11.2B
| $8.09M | 0.06% |
85,582
-11,145
| -12% | -$1.05M |
|
315
Axsome Therapeutics
AXSM
$6.25B
| $8M | 0.05% |
118,602
+2,800
| +2% | +$189K |
|
316
Newmont
NEM
$83.7B
| $7.95M | 0.05% |
125,397
-81,804
| -39% | -$5.18M |
|
317
Neurocrine Biosciences
NBIX
$14.3B
| $7.93M | 0.05% |
81,493
-80,376
| -50% | -$7.82M |
|
318
Precision BioSciences
DTIL
$59.8M
| $7.93M | 0.05% |
+21,105
| New | +$7.93M |
|
319
DaVita
DVA
$9.86B
| $7.92M | 0.05% |
65,777
+25,160
| +62% | +$3.03M |
|
|
SAGE
320
DELISTED
Sage Therapeutics
SAGE
| $7.87M | 0.05% |
138,568
-6,079
| -4% | -$345K |
|
321
Healthpeak Properties
DOC
$12.8B
| $7.81M | 0.05% |
234,461
+190,101
| +429% | +$6.33M |
|
322
Louisiana-Pacific
LPX
$6.9B
| $7.76M | 0.05% |
+128,748
| New | +$7.76M |
|
323
Jack Henry & Associates
JKHY
$11.8B
| $7.7M | 0.05% |
47,084
+42,727
| +981% | +$6.99M |
|
324
FibroGen
FGEN
$48.9M
| $7.68M | 0.05% |
11,539
+4,154
| +56% | +$2.77M |
|
|
TRIL
325
DELISTED
Trillium Therapeutics Inc.
TRIL
| $7.66M | 0.05% |
790,098
+790,056
| +1,881,086% | +$7.66M |
|